CD8A and neoplasm: Similarly, liposomes bearing anti-CD11c scFvs, and containing the model antigen ovalbumin (OVA) and either lipopolysaccharide (LPS) or IFN-γ as adjuvant, improved anti-tumor CD8+ T cell responses and slowed progression of OVA-bearing tumors (46).